{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:21:51Z","timestamp":1781047311572,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82073302"],"award-info":[{"award-number":["No.82073302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81602070"],"award-info":[{"award-number":["No.81602070"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10637-020-01045-7","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T07:10:19Z","timestamp":1610003419000},"page":"836-845","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study"],"prefix":"10.1007","volume":"39","author":[{"given":"Liu-Fang","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Ying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Tao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9657-4380","authenticated-orcid":false,"given":"De-Shen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"4","key":"1045_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Global Burden of Disease Cancer C, Fitzmaurice C, Allen C et al (2017) Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 Cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3(4):524\u2013548. https:\/\/doi.org\/10.1001\/jamaoncol.2016.5688","journal-title":"JAMA Oncol"},{"issue":"9935","key":"1045_CR2","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ (2014) Cholangiocarcinoma. Lancet 383(9935):2168\u20132179","journal-title":"Lancet"},{"issue":"1","key":"1045_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0002-9610(05)80612-9","volume":"159","author":"JL Cameron","year":"1990","unstructured":"Cameron JL, Pitt HA, Zinner MJ et al (1990) Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg 159(1):91\u201398","journal-title":"Am J Surg"},{"issue":"6","key":"1045_CR4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60(6):1268\u20131289. https:\/\/doi.org\/10.1016\/j.jhep.2014.01.021","journal-title":"J Hepatol"},{"issue":"6","key":"1045_CR5","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC (2010) The American joint committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471\u20131474. https:\/\/doi.org\/10.1245\/s10434-010-0985-4","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1045_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s005340170039","volume":"8","author":"M Yamamoto","year":"2001","unstructured":"Yamamoto M, Takasaki K, Otsubo T et al (2001) Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepato-Biliary-Pancreat Surg 8(2):154\u2013157","journal-title":"J Hepato-Biliary-Pancreat Surg"},{"issue":"6","key":"1045_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.surg.2012.12.005","volume":"153","author":"O Hyder","year":"2013","unstructured":"Hyder O, Hatzaras I, Sotiropoulos GC et al (2013) Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 153(6):811\u2013818. https:\/\/doi.org\/10.1016\/j.surg.2012.12.005","journal-title":"Surgery"},{"issue":"6","key":"1045_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"B Glimelius","year":"1996","unstructured":"Glimelius B, Hoffman K, Sj\u00f6d\u00e9n PO et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7(6):593\u2013600","journal-title":"Ann Oncol"},{"issue":"14","key":"1045_CR9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281","journal-title":"N Engl J Med"},{"issue":"9","key":"1045_CR10","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/bjc.2016.64","volume":"114","author":"J Bridgewater","year":"2016","unstructured":"Bridgewater J, Lopes A, Palmer D et al (2016) Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br J Cancer 114(9):965\u2013971. https:\/\/doi.org\/10.1038\/bjc.2016.64","journal-title":"Br J Cancer"},{"key":"1045_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/1471-2407-8-374","volume":"8","author":"M-J Kim","year":"2008","unstructured":"Kim M-J, Oh D-Y, Lee S-H et al (2008) Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC Cancer 8:374. https:\/\/doi.org\/10.1186\/1471-2407-8-374","journal-title":"BMC Cancer"},{"issue":"15_suppl","key":"1045_CR12","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2019.37.15_suppl.4003","volume":"37","author":"A Lamarca","year":"2019","unstructured":"Lamarca A, Palmer DH, Wasan HS et al (2019) ABC-06 | a randomised phase III, multi-Centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin \/ 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced \/ metastatic biliary tract cancers (ABC) previously-treated with cisplatin\/gemcitabine (CisGem) chemotherapy. J Clin Oncol 37(15_suppl):4003\u20134003. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.4003","journal-title":"J Clin Oncol"},{"key":"1045_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.critrevonc.2019.01.001","volume":"139","author":"J Ying","year":"2019","unstructured":"Ying J, Chen J (2019) Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: a comprehensive meta-analysis of published data. Crit Rev Oncol Hematol 139:134\u2013142. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.01.001","journal-title":"Crit Rev Oncol Hematol"},{"issue":"19","key":"1045_CR14","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"issue":"1","key":"1045_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cam4.566","volume":"5","author":"RB Schmuck","year":"2016","unstructured":"Schmuck RB, de Carvalho-Fischer CV, Neumann C et al (2016) Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity. Cancer Med 5(1):88\u201399. https:\/\/doi.org\/10.1002\/cam4.566","journal-title":"Cancer Med"},{"issue":"8","key":"1045_CR16","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamaoncol.2020.2020","volume":"6","author":"H Park","year":"2020","unstructured":"Park H, Jin RU, Wang-Gillam A et al (2020) FOLFIRINOX for the treatment of advanced gastroesophageal cancers: a phase 2 nonrandomized clinical trial. JAMA Oncol 6(8):1231\u20131240. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2020","journal-title":"JAMA Oncol"},{"issue":"suppl 4","key":"1045_CR17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1200\/JCO.2017.35.4_suppl.484","volume":"35","author":"A Rauthan","year":"2017","unstructured":"Rauthan A, Patil P (2017) Modified FOLFIRINOX regimen in advanced biliary tract adenocarcinoma. J Clin Oncol 35(suppl 4):484\u2013484","journal-title":"J Clin Oncol"},{"issue":"10","key":"1045_CR18","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/cncr.31938","volume":"125","author":"MR Sharma","year":"2019","unstructured":"Sharma MR, Joshi SS, Karrison TG et al (2019) A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer 125(10):1629\u20131636","journal-title":"Cancer"},{"issue":"1","key":"1045_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07004-y","volume":"20","author":"A Ulusakarya","year":"2020","unstructured":"Ulusakarya A, Karabou\u00e9 A, Ciacio O et al (2020) A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BMC Cancer 20(1):515. https:\/\/doi.org\/10.1186\/s12885-020-07004-y","journal-title":"BMC Cancer"},{"issue":"suppl 15","key":"1045_CR20","doi-asserted-by":"publisher","first-page":"e15620","DOI":"10.1200\/JCO.2017.35.15_suppl.e15620","volume":"35","author":"BM Kim","year":"2017","unstructured":"Kim BM, Armenio VA (2017) Efficacy and safety of FOLFIRINOX in advanced cholangiocarcinoma. J Clin Oncol 35(suppl 15):e15620\u2013e15620","journal-title":"J Clin Oncol"},{"issue":"2","key":"1045_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12029-016-9880-y","volume":"48","author":"T Kus","year":"2017","unstructured":"Kus T, Aktas G, Kalender ME et al (2017) Comparison of FOLFIRINOX chemotherapy with other regimens in patients with biliary tract cancers: a retrospective study. J Gastrointest Cancer 48(2):170\u2013175. https:\/\/doi.org\/10.1007\/s12029-016-9880-y","journal-title":"J Gastrointest Cancer"},{"issue":"5","key":"1045_CR22","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41416-019-0698-9","volume":"122","author":"A Belkouz","year":"2020","unstructured":"Belkouz A, de Vos-Geelen J, Math\u00f4t RAA et al (2020) Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. Br J Cancer 122(5):634\u2013639. https:\/\/doi.org\/10.1038\/s41416-019-0698-9","journal-title":"Br J Cancer"},{"issue":"3","key":"1045_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.clcc.2018.03.007","volume":"17","author":"PLSU Junior","year":"2018","unstructured":"Junior PLSU, Rother ET, Maluf FC et al (2018) Meta-analysis of modified FOLFIRINOX regimens for patients with metastatic pancreatic cancer. Clin Colorectal Cancer 17(3):187\u2013197","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"1045_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40880-019-0367-7","volume":"39","author":"Z-Q Wang","year":"2019","unstructured":"Wang Z-Q, Zhang F, Deng T et al (2019) The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer Commun (Lond) 39(1):26. https:\/\/doi.org\/10.1186\/s40880-019-0367-7","journal-title":"Cancer Commun (Lond)"},{"issue":"9","key":"1045_CR25","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/bjc.2014.190","volume":"110","author":"L Fornaro","year":"2014","unstructured":"Fornaro L, Cereda S, Aprile G et al (2014) Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer 110(9):2165\u20132169. https:\/\/doi.org\/10.1038\/bjc.2014.190","journal-title":"Br J Cancer"},{"key":"1045_CR26","doi-asserted-by":"publisher","unstructured":"Neuzillet C, Casadei Gardini A, Brieau B et al (2019) Prediction of survival with second-line therapy in biliary tract cancer: actualisation of the AGEO CT2BIL cohort and European multicentre validations. Eur J Cancer 111. https:\/\/doi.org\/10.1016\/j.ejca.2019.01.019","DOI":"10.1016\/j.ejca.2019.01.019"},{"issue":"4","key":"1045_CR27","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.4143\/crt.2017.526","volume":"50","author":"C Yoo","year":"2018","unstructured":"Yoo C, Han B, Kim HS et al (2018) Multicenter phase II study of Oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract Cancer. Cancer Res Treat 50(4):1324\u20131330. https:\/\/doi.org\/10.4143\/crt.2017.526","journal-title":"Cancer Res Treat"},{"issue":"6","key":"1045_CR28","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L et al (2019) Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol 5(6):824\u2013830. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0270","journal-title":"JAMA Oncol"},{"issue":"1","key":"1045_CR29","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1186\/s12885-019-6142-y","volume":"19","author":"L Perkhofer","year":"2019","unstructured":"Perkhofer L, Berger AW, Beutel AK et al (2019) Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study. BMC Cancer 19(1):990. https:\/\/doi.org\/10.1186\/s12885-019-6142-y","journal-title":"BMC Cancer"},{"issue":"1","key":"1045_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000479970","volume":"94","author":"FO Larsen","year":"2018","unstructured":"Larsen FO, Markussen A, Diness LV et al (2018) Efficacy and safety of Capecitabine, irinotecan, gemcitabine, and bevacizumab as second-line treatment in advanced biliary tract Cancer: a phase II study. Oncology 94(1):19\u201324. https:\/\/doi.org\/10.1159\/000479970","journal-title":"Oncology"},{"issue":"7","key":"1045_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/bjc.2016.45","volume":"114","author":"SM Stein","year":"2016","unstructured":"Stein SM, James ES, Deng Y et al (2016) Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 114(7):737\u2013743. https:\/\/doi.org\/10.1038\/bjc.2016.45","journal-title":"Br J Cancer"},{"issue":"5","key":"1045_CR32","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/liv.14063","volume":"39","author":"N Schweitzer","year":"2019","unstructured":"Schweitzer N, Kirstein MM, Kratzel A-M et al (2019) Second-line chemotherapy in biliary tract cancer: outcome and prognostic factors. Liver Int 39(5):914\u2013923. https:\/\/doi.org\/10.1111\/liv.14063","journal-title":"Liver Int"},{"issue":"5","key":"1045_CR33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/bjc.2016.446","volume":"116","author":"BJ Kim","year":"2017","unstructured":"Kim BJ, Yoo C, Kim K-P et al (2017) Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer 116(5):561\u2013567. https:\/\/doi.org\/10.1038\/bjc.2016.446","journal-title":"Br J Cancer"},{"issue":"24","key":"1045_CR34","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1002\/cncr.30254","volume":"122","author":"M Javle","year":"2016","unstructured":"Javle M, Bekaii-Saab T, Jain A et al (2016) Biliary cancer: utility of next-generation sequencing for clinical management. Cancer 122(24):3838\u20133847","journal-title":"Cancer"},{"issue":"9","key":"1045_CR35","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L et al (2017) New horizons for precision medicine in biliary tract cancers. Cancer Discov 7(9):943\u2013962","journal-title":"Cancer Discov"},{"issue":"5","key":"1045_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21(5):671\u2013684. https:\/\/doi.org\/10.1016\/S1470-2045(20)30109-1","journal-title":"Lancet Oncol"},{"issue":"6349","key":"1045_CR37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, NY) 357(6349):409\u2013413. https:\/\/doi.org\/10.1126\/science.aan6733","journal-title":"Science (New York, NY)"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01045-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-01045-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01045-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:04:01Z","timestamp":1678511041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-01045-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1045"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-01045-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"3 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study performed in line with the principles of the Declaration of Helsinki. Approval was granted by the ethical committee of Sun Yat-sen University Cancer Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors affirm that the participants have consented to publish their data to the journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The codes in the current study are available from the network.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}